195 related articles for article (PubMed ID: 25322268)
41. Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: recommendation statement from the Canadian Task Force on Preventive Health Care.
Cheung AM; Feig DS; Kapral M; Diaz-Granados N; Dodin S;
CMAJ; 2004 May; 170(11):1665-7. PubMed ID: 15159360
[No Abstract] [Full Text] [Related]
42. Setting the new FRAX reference threshold without bone mineral density in Chinese postmenopausal women.
Liu S; Chen R; Ding N; Wang Q; Huang M; Liu H; Xie Z; Ou Y; Sheng Z
J Endocrinol Invest; 2021 Feb; 44(2):347-352. PubMed ID: 32495298
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of the validity of osteoporosis and fracture risk assessment tools (IOF One Minute Test, SCORE, and FRAX) in postmenopausal Palestinian women.
Kharroubi A; Saba E; Ghannam I; Darwish H
Arch Osteoporos; 2017 Dec; 12(1):6. PubMed ID: 28013446
[TBL] [Abstract][Full Text] [Related]
44. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial.
Jackson RD; Wactawski-Wende J; LaCroix AZ; Pettinger M; Yood RA; Watts NB; Robbins JA; Lewis CE; Beresford SA; Ko MG; Naughton MJ; Satterfield S; Bassford T;
J Bone Miner Res; 2006 Jun; 21(6):817-28. PubMed ID: 16753012
[TBL] [Abstract][Full Text] [Related]
45. Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative.
Drieling RL; LaCroix AZ; Beresford SA; Boudreau DM; Kooperberg C; Chlebowski RT; Gass M; Crandall CJ; Womack CR; Heckbert SR
Menopause; 2016 Nov; 23(11):1168-1175. PubMed ID: 27433859
[TBL] [Abstract][Full Text] [Related]
46. Osteoporosis in the Women's Health Initiative: Another Treatment Gap?
Sattari M; Cauley JA; Garvan C; Johnson KC; LaMonte MJ; Li W; Limacher M; Manini T; Sarto GE; Sullivan SD; Wactawski-Wende J; Beyth RJ
Am J Med; 2017 Aug; 130(8):937-948. PubMed ID: 28366425
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women.
Mueller D; Gandjour A
Value Health; 2009; 12(8):1106-17. PubMed ID: 19706151
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women's Health Initiative.
Mora S; Wenger NK; Cook NR; Liu J; Howard BV; Limacher MC; Liu S; Margolis KL; Martin LW; Paynter NP; Ridker PM; Robinson JG; Rossouw JE; Safford MM; Manson JE
JAMA Intern Med; 2018 Sep; 178(9):1231-1240. PubMed ID: 30039172
[TBL] [Abstract][Full Text] [Related]
49. Postmenopausal health interventions: Time to move on from the Women's Health Initiative?
Thaung Zaw JJ; Howe PRC; Wong RHX
Ageing Res Rev; 2018 Dec; 48():79-86. PubMed ID: 30355506
[TBL] [Abstract][Full Text] [Related]
50. BFH-OST, a new predictive screening tool for identifying osteoporosis in postmenopausal Han Chinese women.
Ma Z; Yang Y; Lin J; Zhang X; Meng Q; Wang B; Fei Q
Clin Interv Aging; 2016; 11():1051-9. PubMed ID: 27536085
[TBL] [Abstract][Full Text] [Related]
51. Association of pelvic organ prolapse and fractures in postmenopausal women: analysis of baseline data from the Women's Health Initiative Estrogen Plus Progestin trial.
Pal L; Hailpern SM; Santoro NF; Freeman R; Barad D; Kipersztok S; Barnabei VM; Wassertheil-Smoller S
Menopause; 2008; 15(1):59-66. PubMed ID: 18257143
[TBL] [Abstract][Full Text] [Related]
52. Fracture risk among treatment-naïve postmenopausal women with osteopenia in Greece: results from the "ACROSS" study.
Anastasilakis AD; Makras P
Arch Osteoporos; 2020 Oct; 15(1):163. PubMed ID: 33067646
[TBL] [Abstract][Full Text] [Related]
53. WHO absolute fracture risk models (FRAX): do clinical risk factors improve fracture prediction in older women without osteoporosis?
Hillier TA; Cauley JA; Rizzo JH; Pedula KL; Ensrud KE; Bauer DC; Lui LY; Vesco KK; Black DM; Donaldson MG; Leblanc ES; Cummings SR
J Bone Miner Res; 2011 Aug; 26(8):1774-82. PubMed ID: 21351144
[TBL] [Abstract][Full Text] [Related]
54. Ultrasonometric profiling of incidence and risk of osteoporosis in rural women.
Gueldner SH; Britton GR; Madhavan G; Pierce CS; Grabo TN; Penrod J; Stucke SA; Liu CF
J Women Aging; 2008; 20(1-2):21-30. PubMed ID: 18581698
[TBL] [Abstract][Full Text] [Related]
55. Clinical use of bone densitometry: scientific review.
Cummings SR; Bates D; Black DM
JAMA; 2002 Oct; 288(15):1889-97. PubMed ID: 12377088
[TBL] [Abstract][Full Text] [Related]
56. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.
Cauley JA; Robbins J; Chen Z; Cummings SR; Jackson RD; LaCroix AZ; LeBoff M; Lewis CE; McGowan J; Neuner J; Pettinger M; Stefanick ML; Wactawski-Wende J; Watts NB;
JAMA; 2003 Oct; 290(13):1729-38. PubMed ID: 14519707
[TBL] [Abstract][Full Text] [Related]
57. Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study.
Chen Z; Maricic M; Bassford TL; Pettinger M; Ritenbaugh C; Lopez AM; Barad DH; Gass M; Leboff MS
Arch Intern Med; 2005 Mar; 165(5):552-8. PubMed ID: 15767532
[TBL] [Abstract][Full Text] [Related]
58. Simple computer model for calculating and reporting 5-year osteoporotic fracture risk in postmenopausal women.
Ettinger B; Hillier TA; Pressman A; Che M; Hanley DA
J Womens Health (Larchmt); 2005 Mar; 14(2):159-71. PubMed ID: 15775734
[TBL] [Abstract][Full Text] [Related]
59. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.
Barrett-Connor E; Wehren LE; Siris ES; Miller P; Chen YT; Abbott TA; Berger ML; Santora AC; Sherwood LM
Menopause; 2003; 10(5):412-9. PubMed ID: 14501602
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
